Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8

Blood

Volumn 98, Issue 4, 2001, Pages 1252-1254

  Arepally, Gowthami M ^a,b   Mayer, Irene M ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b Department of Pathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HEPARIN; INTERLEUKIN 8; MONOCLONAL ANTIBODY; PROCOAGULANT; THROMBOCYTE FACTOR 4; THROMBOPLASTIN;

ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; LEUKOCYTE ACTIVATION; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA; THROMBOGENESIS;

EID: 0035883078     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.4.1252     Document Type: Article

References (22)

1. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96:1703-1708.
2. Reilly MP, Taylor SM, Hartman NK, et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood. In press.
3. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
4. Warkentin TE, Elavathil LJ, Hayward CP, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127:804-812.
5. Ortel TL, Chong BH. New treatment options for heparin-induced thrombocytopenia. Semin Hematol. 1998;35:26-34.
6. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med. 1987;316:581-589.
7. Herbert JM, Savi P, Jeske WP, Walenga JM. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb Haemoco. 1998;80:326-331.
8. Lyberg T, Prydz H, Baklien K, Hoyeraal HM. Effect of immune complex-containing sera from patients with rheumatic diseases on thromboplastin activity of monocytes. Thromb Res. 1982;25:193-202.
9. Reverter JC, Tassies D, Font J, et al. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free proteins. Arterioscler Thromb Vasc Biol. 1996;16:1319-1326.
10. Rivers RP, Hathaway WE, Weston WL. The endotoxin-induced coagulant activity of human monocytes. Br J Haematol. 1975;30:311-316.
11. Khajuria A, Houston DS. Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis. Blood. 2000;96:966-972.
12. Arepally GM, Kamei S, Park KS, et al. Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. Blood. 2000;95:1533-1540.
13. Biswas P, Delfanti F, Bernasconi S, et al. Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood. 1998;91:258-265.
14. Aida Y, Pabst MJ. Removal of endotoxin from protein solutions by phase separation using Triton X-114. J Immunol Methods. 1990;132:191-195.
15. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A. 1999;96:2311-2315.
16. Pouplard C, Iochmann S, Renard M, et al. Induction of monocyte tissue factor expression by antibodies to platelet factor 4 developed in heparininduced thrombocytopenia. Blood. 2001;97:33003302.
17. Plescia J, Altieri DC. Activation of Mac-1 (CDIIb/CD 18)-bound factor X by released cathepsin G defines an alternative pathway of leucocyte initiation of coagulation. Biochem J. 1996;319:873-879.
18. Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett. 1992;307:97-101.
19. Amiral J, Marfaing-Koka A, Wolf M, et al. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood. 1996;88:410-416.
20. Baugh MJ, Prechel M, Hoppensteadt D, Wallis E, Bick RL, Walenga JM. The role of CD40 ligand and anti-annexin V antibodies in the pathophysiology of APS and HIT. Blood. 2000;96:272a.
21. Jeske W, Vasaiwala S, Schlenker R, Wallis E, Walenga JM. Leukocyte activation in heparininduced thrombocytopenia. Blood. 2000;96:29b.
22. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507.